Reuters logo
BRIEF-Sage Therapeutics reports top-line results from Phase 3 STATUS trial of brexanolone
2017年9月12日 / 上午10点22分 / 14 天前

BRIEF-Sage Therapeutics reports top-line results from Phase 3 STATUS trial of brexanolone

Sept 12 (Reuters) - Sage Therapeutics Inc

* Sage Therapeutics reports top-line results from Phase 3 STATUS trial of brexanolone in super-refractory status epilepticus

* Sage Therapeutics Inc - ‍study did not meet primary endpoint​

* Sage Therapeutics Inc - ‍secondary endpoint results were consistent with primary endpoint in study​

* Sage Therapeutics Inc - ‍rate of death was similar in brexanolone and placebo groups in study​

* Sage Therapeutics Inc - ‍rate of adverse events leading to discontinuation of study drug was similar in brexanolone and placebo groups and was low overall​

* Sage Therapeutics Inc - ‍serious adverse events were similar between two treatment groups in trial​

* Sage Therapeutics - about 37 percent of patients treated with open-label brexanolone after end of double-blind period achieved treatment response​ Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below